290 related articles for article (PubMed ID: 27823638)
1. Molecular characteristics of biliary tract cancer.
Sohal DP; Shrotriya S; Abazeed M; Cruise M; Khorana A
Crit Rev Oncol Hematol; 2016 Nov; 107():111-118. PubMed ID: 27823638
[TBL] [Abstract][Full Text] [Related]
2. Genomic Profiling of Biliary Tract Cancers and Implications for Clinical Practice.
Jain A; Kwong LN; Javle M
Curr Treat Options Oncol; 2016 Nov; 17(11):58. PubMed ID: 27658789
[TBL] [Abstract][Full Text] [Related]
3. Molecular targeted therapies: Ready for "prime time" in biliary tract cancer.
Lamarca A; Barriuso J; McNamara MG; Valle JW
J Hepatol; 2020 Jul; 73(1):170-185. PubMed ID: 32171892
[TBL] [Abstract][Full Text] [Related]
4. Targeted therapies in advanced biliary tract cancers-a narrative review.
LaPelusa M; Heumann T; Goff L; Agarwal R
Chin Clin Oncol; 2023 Apr; 12(2):14. PubMed ID: 36946186
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention.
Lowery MA; Ptashkin R; Jordan E; Berger MF; Zehir A; Capanu M; Kemeny NE; O'Reilly EM; El-Dika I; Jarnagin WR; Harding JJ; D'Angelica MI; Cercek A; Hechtman JF; Solit DB; Schultz N; Hyman DM; Klimstra DS; Saltz LB; Abou-Alfa GK
Clin Cancer Res; 2018 Sep; 24(17):4154-4161. PubMed ID: 29848569
[No Abstract] [Full Text] [Related]
6. Biliary cancer: Utility of next-generation sequencing for clinical management.
Javle M; Bekaii-Saab T; Jain A; Wang Y; Kelley RK; Wang K; Kang HC; Catenacci D; Ali S; Krishnan S; Ahn D; Bocobo AG; Zuo M; Kaseb A; Miller V; Stephens PJ; Meric-Bernstam F; Shroff R; Ross J
Cancer; 2016 Dec; 122(24):3838-3847. PubMed ID: 27622582
[TBL] [Abstract][Full Text] [Related]
7. Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design.
Sicklick JK; Fanta PT; Shimabukuro K; Kurzrock R
Cancer Metastasis Rev; 2016 Jun; 35(2):263-75. PubMed ID: 26857926
[TBL] [Abstract][Full Text] [Related]
8. Cell of origin in biliary tract cancers and clinical implications.
Moeini A; Haber PK; Sia D
JHEP Rep; 2021 Apr; 3(2):100226. PubMed ID: 33665585
[TBL] [Abstract][Full Text] [Related]
9. EGFR and HER2 expression in advanced biliary tract cancer.
Harder J; Waiz O; Otto F; Geissler M; Olschewski M; Weinhold B; Blum HE; Schmitt-Graeff A; Opitz OG
World J Gastroenterol; 2009 Sep; 15(36):4511-7. PubMed ID: 19777609
[TBL] [Abstract][Full Text] [Related]
10. Biliary Tract Cancer: Epidemiology, Radiotherapy, and Molecular Profiling.
Bridgewater JA; Goodman KA; Kalyan A; Mulcahy MF
Am Soc Clin Oncol Educ Book; 2016; 35():e194-203. PubMed ID: 27249723
[TBL] [Abstract][Full Text] [Related]
11. Molecular Targets in Biliary Carcinogenesis and Implications for Therapy.
Oyasiji T; Zhang J; Kuvshinoff B; Iyer R; Hochwald SN
Oncologist; 2015 Jul; 20(7):742-51. PubMed ID: 26025932
[TBL] [Abstract][Full Text] [Related]
12. Current biologics for treatment of biliary tract cancers.
Zhao DY; Lim KH
J Gastrointest Oncol; 2017 Jun; 8(3):430-440. PubMed ID: 28736630
[TBL] [Abstract][Full Text] [Related]
13. Advances in biomarkers of biliary tract cancers.
Hu J; Yin B
Biomed Pharmacother; 2016 Jul; 81():128-135. PubMed ID: 27261586
[TBL] [Abstract][Full Text] [Related]
14. Current and emerging therapies for advanced biliary tract cancers.
Kam AE; Masood A; Shroff RT
Lancet Gastroenterol Hepatol; 2021 Nov; 6(11):956-969. PubMed ID: 34626563
[TBL] [Abstract][Full Text] [Related]
15. Novel targeted treatment options for advanced cholangiocarcinoma.
Mahipal A; Kommalapati A; Tella SH; Lim A; Kim R
Expert Opin Investig Drugs; 2018 Sep; 27(9):709-720. PubMed ID: 30124336
[TBL] [Abstract][Full Text] [Related]
16. The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets.
Chong DQ; Zhu AX
Oncotarget; 2016 Jul; 7(29):46750-46767. PubMed ID: 27102149
[TBL] [Abstract][Full Text] [Related]
17. Biliary tract cancer.
Valle JW; Kelley RK; Nervi B; Oh DY; Zhu AX
Lancet; 2021 Jan; 397(10272):428-444. PubMed ID: 33516341
[TBL] [Abstract][Full Text] [Related]
18. Broadening the therapeutic horizon of advanced biliary tract cancer through molecular characterisation.
Athauda A; Fong C; Lau DK; Javle M; Abou-Alfa GK; Morizane C; Steward K; Chau I
Cancer Treat Rev; 2020 Jun; 86():101998. PubMed ID: 32203843
[TBL] [Abstract][Full Text] [Related]
19. Optimizing Patient Pathways in Advanced Biliary Tract Cancers: Recent Advances and a French Perspective.
Neuzillet C; Artru P; Assenat E; Edeline J; Adhoute X; Sabourin JC; Turpin A; Coriat R; Malka D
Target Oncol; 2023 Jan; 18(1):51-76. PubMed ID: 36745342
[TBL] [Abstract][Full Text] [Related]
20. [Not Available].
Valéry M; Cervantes B; Smolenschi C; Boige V; Ducreux M; Cohen R; Hollebecque A
Bull Cancer; 2022 Nov; 109(11S):11S21-11S27. PubMed ID: 36535759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]